Ranbaxy Laboratories http://www.globalpost.com/taxonomy/term/35922/all en India's Ranbaxy surprises with quarterly loss http://www.globalpost.com/dispatch/news/afp/130226/indias-ranbaxy-surprises-quarterly-loss <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>India's largest drug firm Ranbaxy reported Tuesday a sharp narrowing of its quarterly net loss but missed analyst forecasts for a profit after it was hit by product recall charges.</p> <p>The generics drug maker, majority-owned by Japan's Daiichi Sankyo, posted a net loss of 4.92 billion rupees ($91 million) for the three months to December, down from a loss of 29.83 billion rupees a year earlier.</p> <p>But analysts had expected Ranbaxy to be in the black for the fourth quarter and report a net profit of around 2.2 billion rupees, according to a poll by Dow Jones Newswires.</p> <p><a href="http://www.globalpost.com/dispatch/news/afp/130226/indias-ranbaxy-surprises-quarterly-loss" target="_blank">read more</a></p> BSE Sensex Daiichi Sankyo Entertainment Ranbaxy Laboratories Ranbaxy Laboratories AFP Tue, 26 Feb 2013 16:16:11 +0000 5767366 at http://www.globalpost.com Hashimoto clarifies remarks on "comfort women" after flak http://www.globalpost.com/dispatch/news/kyodo-news-international/130507/refiling-update1-japan-taiwan-end-joint-fishing-commit <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Kyodo News International </div> </div> </div> <!--paging_filter--><p> Osaka Mayor Toru Hashimoto on Wednesday sought to clarify his remarks on a system to recruit women into sexual servitude for Japan's soldiers during World War II, saying he personally does not condone the scheme.</p> <p> Two days after he made controversial remarks that the so-called comfort women were "necessary to maintain discipline" in the Japanese military, Hashimoto told reporters he simply stated a fact that people at the time had that kind of view.</p> <p><a href="http://www.globalpost.com/dispatch/news/kyodo-news-international/130507/refiling-update1-japan-taiwan-end-joint-fishing-commit" target="_blank">read more</a></p> Abe Arctic Ashwani Kumar Asia Awami National Party Barack Obama British knights BSE Sensex Business Carrier Strike Group Eleven Chemistry Corruption in India Crimes against humanity Cross-Strait relations Cruise ships Daiichi Sankyo Dance in Japan Divided regions Economic history Economics Economy of Japan Election fraud Elections Energy Energy conversion Environment Ethics Films Finance Financial planner Fiscal policy G-7 Gambling in Japan Geography of Asia Government Greenhouse gases Health Independent Commission Against Corruption Inflation International criminal law International economics International relations International trade Island countries Japan Japanese people Japan–United States relations Kim Jong-il Korea Kyushu region Labor Law Liberal democracies Liberal Democratic Party Macroeconomics Mass media Member states of the United Nations Memoirists Muslim League Muttahida Qaumi Movement North Korea North Korea North Korea–South Korea relations Nuclear physics Nuclear program of North Korea Nuclear technology Okinawa Prefecture Osaka Pakistan Pakistani politicians Physical geography Poetry Political geography Politics Politics of India Politics of Japan Politics of Pakistan Polling place Public finance Ranbaxy Laboratories Republics Secularism Secularism in Pakistan Senkaku Islands Shinzō Abe Shinzo Abe Social Issues Sōka Gakkai Taipei Taiwanese culture Taliban Technology Toru Hashimoto Tōru Hashimoto Trans-Pacific Partnership Unemployment United States trade policy USS Nimitz Volcanism War Yonhap Yoon Yoriko Kawaguchi YTN Group Kyodo News International Tue, 07 May 2013 16:30:16 +0000 5832850 at http://www.globalpost.com Ranbaxy pleads guilty, to pay $500 million in U.S. settlement http://www.globalpost.com/dispatch/news/thomson-reuters/130513/ranbaxy-pleads-guilty-pay-500-million-us-settlement <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Thomson Reuters </div> </div> </div> <!--paging_filter--><p>(Reuters) - Indian generic drugmaker Ranbaxy Laboratories Ltd pleaded guilty on Monday to felony charges related to drug safety and will pay $500 million in civil and criminal fines under the settlement agreement with the U.S. Department of Justice.</p> <p>The settlement is its largest-ever with a generic drugmaker over drug safety, according to the U.S. government. It includes $150 million in payments for a criminal fine and forfeiture and $350 million in payments for civil claims.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://thomsonreuters.com" class="button wire reuters"></a></p> <p><span>Copyright Thomson Reuters, 2013.</span></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/thomson-reuters/130513/ranbaxy-pleads-guilty-pay-500-million-us-settlement" target="_blank">read more</a></p> BSE Sensex Health Labor Pharmaceutical sciences Ranbaxy Laboratories Social Issues Thomson Reuters Mon, 13 May 2013 18:45:43 +0000 5836897 at http://www.globalpost.com India's Ranbaxy shares climb as US legal battle ends http://www.globalpost.com/dispatch/news/afp/130514/indias-ranbaxy-shares-climb-us-legal-battle-ends <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>Shares in Ranbaxy climbed on Tuesday after US authorities slapped a $500 million fine on India's biggest drugmaker to settle a lengthy lawsuit over the sale of adulterated drugs in the United States.</p> <p>The case -- the largest-ever US drug safety settlement with a generic manufacturer -- ended eight years of criminal and civil investigations into the company, which is now majority-owned by Japan's Daiichi Sankyo.</p> <p>After opening down over four percent, Ranbaxy shares closed up 3.63 percent at 455.5 rupees as analysts said the decision would allow the firm to focus on the future.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://www.afp.com/" class="button wire afp"></a></p> <p><a href="http://www.globalpost.com/terms-use#afp"><span>Copyright AFP, 2013.</span></a></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/afp/130514/indias-ranbaxy-shares-climb-us-legal-battle-ends" target="_blank">read more</a></p> BSE Sensex Business Pharmaceutical sciences Ranbaxy Laboratories Ranbaxy Laboratories AFP Tue, 14 May 2013 13:01:29 +0000 5837451 at http://www.globalpost.com Japan's Daiichi says key details 'concealed' in Ranbaxy sale http://www.globalpost.com/dispatch/news/afp/130522/japans-daiichi-says-key-details-concealed-ranbaxy-sale <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>The Japanese owners of Ranbaxy on Wednesday accused former shareholders of the Indian company of concealing key information about a US probe into the safety of medicines made by the New Delhi-based firm.</p> <p>Last week, Ranbaxy Laboratories pleaded guilty in the United States to charges of making and distributing adulterated drugs at its two Indian plants of Paonta Sahib and Dewas and agreed to a $500 million settlement.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://www.afp.com/" class="button wire afp"></a></p> <p><a href="http://www.globalpost.com/terms-use#afp"><span>Copyright AFP, 2013.</span></a></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/afp/130522/japans-daiichi-says-key-details-concealed-ranbaxy-sale" target="_blank">read more</a></p> BSE Sensex Business Daiichi Sankyo Labor Law Ranbaxy Laboratories Ranbaxy Laboratories AFP Wed, 22 May 2013 19:30:16 +0000 5844075 at http://www.globalpost.com Ranbaxy shares dive after Japan parent says was misled http://www.globalpost.com/dispatch/news/afp/130523/ranbaxy-shares-dive-after-japan-parent-says-was-misled <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>Shares of Ranbaxy plunged Thursday after its Japanese parent accused former owners of the Indian firm of hiding key details about a US probe into the safety of drugs made by the generics giant.</p> <p>Last week, Ranbaxy Laboratories pleaded guilty in the United States to charges of making and distributing adulterated drugs at two Indian plants and agreed to a $500 million settlement.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://www.afp.com/" class="button wire afp"></a></p> <p><a href="http://www.globalpost.com/terms-use#afp"><span>Copyright AFP, 2013.</span></a></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/afp/130523/ranbaxy-shares-dive-after-japan-parent-says-was-misled" target="_blank">read more</a></p> BSE Sensex Business Daiichi Sankyo Labor Law Ranbaxy Laboratories Ranbaxy Laboratories AFP Thu, 23 May 2013 08:46:56 +0000 5844494 at http://www.globalpost.com India's Wockhardt shares dive on US import ban http://www.globalpost.com/dispatch/news/afp/130524/indias-wockhardt-shares-dive-us-import-ban <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>Shares of Indian pharmaceuticals firm Wockhardt plunged nearly 19 percent Friday, a day after it said the US drugs regulator had banned imports from one of its manufacturing units over quality concerns.</p> <p>Wockhardt shares fell as far as 18.9 percent to 1,066 rupees ($19) -- a near nine-month-low -- at the Bombay Stock Exchange.</p> <p>Its shares initially fell by 20.1 percent Thursday after the firm said it feared a loss of $100 million in annual revenues due to the import ban issued Wednesday.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://www.afp.com/" class="button wire afp"></a></p> <p><a href="http://www.globalpost.com/terms-use#afp"><span>Copyright AFP, 2013.</span></a></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/afp/130524/indias-wockhardt-shares-dive-us-import-ban" target="_blank">read more</a></p> Economy of India Ranbaxy Laboratories Technology Wockhardt AFP Fri, 24 May 2013 08:15:28 +0000 5845311 at http://www.globalpost.com More pain for Japan's Daiichi hit by Ranbaxy fraud http://www.globalpost.com/dispatch/news/afp/130609/more-pain-japans-daiichi-hit-ranbaxy-fraud <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>Daiichi Sankyo believed it had scored a coup in 2008 when it outbid rivals to buy Indian generics giant Ranbaxy for $4.6 billion but its foray into the high-growth copycat drugs arena has brought the Japanese drugmaker only pain.</p> <p>Last month, Ranbaxy pleaded guilty to US charges of selling adulterated antibiotic, acne, epilepsy and other drugs and agreed to a record $500-million fine, and since then the bad news has kept on flowing.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://www.afp.com/" class="button wire afp"></a></p> <p><a href="http://www.globalpost.com/terms-use#afp"><span>Copyright AFP, 2013.</span></a></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/afp/130609/more-pain-japans-daiichi-hit-ranbaxy-fraud" target="_blank">read more</a></p> BSE Sensex Business Daiichi Sankyo Hospitality Labor Law Politics Ranbaxy Ranbaxy Laboratories Social Issues AFP Sun, 09 Jun 2013 04:44:42 +0000 5853390 at http://www.globalpost.com India's Ranbaxy falls on media report of U.S. FDA query on plant http://www.globalpost.com/dispatch/news/thomson-reuters/130624/indias-ranbaxy-falls-media-report-us-fda-query-plant <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Thomson Reuters </div> </div> </div> <!--paging_filter--><p>MUMBAI (Reuters) - Shares of Ranbaxy Laboratories Ltd fell as much as 2.3 percent on Monday after newspaper Business Standard reported the U.S. Food and Drug Administration had raised concerns about a plant in northern India, citing unidentified sources.</p> <p>Business Standard said the FDA had issued form 483 to Ranbaxy regarding its Mohali plant. That form is issued when U.S. inspectors see conditions they believe may violate U.S. rules.</p> <p>A Ranbaxy spokesman declined to comment when asked if the drug maker had received the 483 form.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://thomsonreuters.com" class="button wire reuters"></a></p> <p><span>Copyright Thomson Reuters, 2013.</span></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/thomson-reuters/130624/indias-ranbaxy-falls-media-report-us-fda-query-plant" target="_blank">read more</a></p> BSE Sensex Pharmaceutical sciences Ranbaxy Laboratories Thomson Reuters Mon, 24 Jun 2013 06:03:57 +0000 5865421 at http://www.globalpost.com Indian drugmaker Ranbaxy faces new US regulation woes http://www.globalpost.com/dispatch/news/afp/130916/indian-drugmaker-ranbaxy-faces-new-us-regulation-woes <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>Shares in Indian generic drugs giant Ranbaxy Laboratories crashed as much as 35 percent in early trade on Monday after the US Food and Drug Administration suspended imports from one of its factories.</p> <p>Ranbaxy slid to 297.25 rupees on the Bombay Stock Exchange, down 34.99 percent, before recovering to 341.00 rupees, down 25.42 percent.</p> <p>The FDA issued an alert on Friday against a Ranbaxy factory in Mohali in the northern state of Punjab, meaning imports are suspended from the plant.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://www.afp.com/" class="button wire afp"></a></p> <p><a href="http://www.globalpost.com/terms-use#afp"><span>Copyright AFP, 2013.</span></a></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/afp/130916/indian-drugmaker-ranbaxy-faces-new-us-regulation-woes" target="_blank">read more</a></p> BSE Sensex Business Daiichi Sankyo Health Labor Law Ranbaxy Laboratories Social Issues AFP Mon, 16 Sep 2013 06:49:12 +0000 5935292 at http://www.globalpost.com India's Ranbaxy promises to address issues over US ban http://www.globalpost.com/dispatch/news/afp/130917/indias-ranbaxy-promises-address-issues-over-us-ban <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>India's Ranbaxy Laboratories, one of world's biggest generic drug makers, said Tuesday it would take "all necessary steps" to help lift an import ban by the US health regulator on one of its factories.</p> <p>The US Food and Drugs Administration (FDA) issued an alert on Friday against the factory at Mohali in the northern state of Punjab, spelling more bad news for the company that has been marred by nearly 10 years of US-led regulatory action.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://www.afp.com/" class="button wire afp"></a></p> <p><a href="http://www.globalpost.com/terms-use#afp"><span>Copyright AFP, 2013.</span></a></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/afp/130917/indias-ranbaxy-promises-address-issues-over-us-ban" target="_blank">read more</a></p> BSE Sensex Business Labor Law Pharmaceutical sciences Ranbaxy Laboratories Ranbaxy Laboratories AFP Tue, 17 Sep 2013 15:31:27 +0000 5936388 at http://www.globalpost.com Suspected human hair in tablet cited in FDA's Ranbaxy import ban http://www.globalpost.com/dispatch/news/thomson-reuters/130918/suspected-human-hair-tablet-cited-fdas-ranbaxy-import-ban <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Thomson Reuters </div> </div> </div> <!--paging_filter--><p>By Sumeet Chatterjee</p> <p>(Reuters) - During a visit to a facility of leading Indian drugmaker Ranbaxy Laboratories Ltd last year, U.S. inspectors found that a black fiber embedded in a tablet may have been a hair from an employee's arm, according to documents seen by Reuters.</p> <p>That and other quality concerns led the U.S. Food and Drug Administration to impose an "import alert" on its Mohali plant last week, saying the factory owned by India's biggest drugmaker by sales had not ensured manufacturing quality.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://thomsonreuters.com" class="button wire reuters"></a></p> <p><span>Copyright Thomson Reuters, 2013.</span></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/thomson-reuters/130918/suspected-human-hair-tablet-cited-fdas-ranbaxy-import-ban" target="_blank">read more</a></p> BSE Sensex Business Health Labor Law Pharmaceutical sciences Ranbaxy Laboratories Social Issues Thomson Reuters Wed, 18 Sep 2013 11:17:56 +0000 5937369 at http://www.globalpost.com Wockhardt profit dives as faces U.S., UK regulator demands http://www.globalpost.com/dispatch/news/thomson-reuters/131025/wockhardt-profit-dives-faces-us-uk-regulator-demands <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Thomson Reuters </div> </div> </div> <!--paging_filter--><p>By Aradhana Aravindan and Sumeet Chatterjee</p> <p>MUMBAI (Reuters) - Wockhardt Ltd faces a year or more to get U.S. and British regulators to end curbs on its shipments of medicines to the two countries, the Indian drugmaker said on Friday after posting its smallest profit in six quarters.</p> <p>Indian firms, which make nearly 40 percent of generic and over-the-counter drugs for the U.S. market, face more regulatory woes, including a record fine for Ranbaxy Laboratories, amid increased scrutiny by overseas regulators.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://thomsonreuters.com" class="button wire reuters"></a></p> <p><span>Copyright Thomson Reuters, 2013.</span></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/thomson-reuters/131025/wockhardt-profit-dives-faces-us-uk-regulator-demands" target="_blank">read more</a></p> International Organization of Securities Commissions Ranbaxy Laboratories Wockhardt Wockhardt Ltd Thomson Reuters Fri, 25 Oct 2013 18:16:07 +0000 5971019 at http://www.globalpost.com Indian drug giant Ranbaxy trims losses but future is bleaker http://www.globalpost.com/dispatch/news/afp/140205/indian-drug-giant-ranbaxy-trims-losses-future-bleaker <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>Ranbaxy Laboratories, India's biggest generic drugmaker by sales, reported a narrower quarterly loss on Wednesday thanks to rising sales in key markets and currency gains.</p> <p>But Ranbaxy, majority-owned by Japan's Daiichi Sankyo, faces an uphill battle to repeat the performance next quarter after the US Food and Drug Administration slapped another import ban on the company's products.</p> <p>The FDA announced the ban last month, citing concerns about "good manufacturing practice" at a plant in northern India. The move is expected to put severe pressure on future earnings.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://www.afp.com/" class="button wire afp"></a></p> <p><a href="http://www.globalpost.com/terms-use#afp"><span>Copyright AFP, 2014.</span></a></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/afp/140205/indian-drug-giant-ranbaxy-trims-losses-future-bleaker" target="_blank">read more</a></p> BSE Sensex Pharmaceutical sciences Ranbaxy Laboratories Ranbaxy Laboratories Technology AFP Wed, 05 Feb 2014 13:38:02 +0000 6062206 at http://www.globalpost.com Indian drugmaker Ranbaxy suspends shipments after US bans http://www.globalpost.com/dispatch/news/afp/140225/indian-drugmaker-ranbaxy-suspends-shipments-after-us-bans <div class="field field-type-text field-field-byline1"> <div class="field-items"> <div class="field-item odd"> Agence France-Presse </div> </div> </div> <!--paging_filter--><p>Indian drugmaking giant Ranbaxy Laboratories said Tuesday it was suspending shipments from two of its plants following US import bans on its products over safety concerns.</p> <p>In a filing to the Bombay Stock Exchange, Ranbaxy said it was "temporarily putting on hold" shipments of active pharmaceutical ingredients from facilities at two of its plants -- Toansa in the northwest and Dewas in central India.</p> <div class="field field-type-text field-field-wire-copyright"> <div class="field-items"> <div class="field-item odd"> <p><a href="http://www.afp.com/" class="button wire afp"></a></p> <p><a href="http://www.globalpost.com/terms-use#afp"><span>Copyright AFP, 2014.</span></a></p> </div> </div> </div> <p><a href="http://www.globalpost.com/dispatch/news/afp/140225/indian-drugmaker-ranbaxy-suspends-shipments-after-us-bans" target="_blank">read more</a></p> BSE Sensex Business Madhya Pradesh Ranbaxy Laboratories Ranbaxy Laboratories AFP Tue, 25 Feb 2014 15:10:32 +0000 6080230 at http://www.globalpost.com